Erik Swain

CHICAGO — A novel nasal spray formulation of bumetanide, a commonly used diuretic for patients with HF, had similar safety, tolerability, relative bioavailability and pharmacodynamics to the oral and IV versions, researchers reported. The results of the phase 1 RSQ-777-02 study of nasal, oral and IV bumetanide in healthy volunteers were presented at the American Heart Association Scientific

CHICAGO — People living in historically redlined neighborhoods with poor access to healthy foods were more likely to have type 2 diabetes, hypertension, coronary heart disease and obesity, researchers reported.

CHICAGO — U.S. out-of-hospital cardiac arrest survival rates have improved since the first year of the COVID-19 pandemic, but have not returned to pre-pandemic levels, researchers reported.“The onset of the COVID-19 pandemic marked an abrupt change in health care delivery systems and imposed a substantial stress on frontline providers. Initial studies during the early phases of the

CHICAGO — A potassium binder helped patients with HF who have or are at high risk for hyperkalemia stay on spironolactone at an optimal dose, but showed a signal of HF hospitalization risk, researchers reported.For the REALIZE-K trial, presented at the American Heart Association Scientific Sessions and simultaneously published in the Journal of the American College of Cardiology, Mikhail

Healthy adults who fasted for the entirety of simulated night-shift work displayed compensatory hyperinsulinemia and maintained glucose tolerance compared with participants who consumed a meal or snack, study results showed.

Video Player is loading. Play Video Play Mute Current Time Duration Loaded

GLP-1 receptor agonists improved clinical outcomes related to kidney and heart health while lowering mortality rates for individuals with diabetes, chronic kidney disease or preexisting cardiovascular disease with overweight or obesity.“GLP-1 receptor agonists not only lower blood glucose levels and body weight, but also have kidney-protective and heart-protective benefits,” Sunil V.

CHICAGO — Zerlasiran, a novel injectable small interfering RNA molecule, lowered lipoprotein(a) by more than 80% compared with placebo at 36 weeks, according to the results of the ALPACAR trial.The phase 2 ALPACAR trial, results of which were presented at the American Heart Association Scientific Sessions and simultaneously published in JAMA, included 178 patients (mean age, 63.7 years;

SAN ANTONIO — In this Healio video exclusive, Katherine H. Saunders, MD, DABOM , discusses important considerations for appropriate prescription of weight-loss medications.

CHICAGO — When race was removed from the MESA risk prediction score, its ability to predict risk for heart disease did not change significantly, researchers reported at the American Heart Association Scientific Sessions.